Open Access

Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro

  • Authors:
    • Gaku Moriyama
    • Maya Tanigawa
    • Kosuke Sakai
    • Yusuke Hirata
    • Satoshi Kikuchi
    • Yuriko Saito
    • Hiroyuki Kyoyama
    • Kuniko Matsuda
    • Masahiro Seike
    • Akihiko Gemma
    • Kazutsugu Uematsu
  • View Affiliations

  • Published online on: November 9, 2017     https://doi.org/10.3892/ol.2017.7382
  • Pages:833-838
  • Copyright: © Moriyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

It was previously revealed that Wnt signaling is activated in mesothelioma cells. Although epidermal growth factor receptor (EGFR) is expressed in mesothelioma cells, EGFR‑tyrosine kinase inhibitors (TKIs) are not effective for mesothelioma treatment. However, in non‑small cell lung cancer, the blocking of Wnt signaling has been identified to enhance the anticancer effect of EGFR‑TKIs. To confirm the anticancer effect of blocking Wnt signaling in combination with EGFR‑TKI treatment in mesothelioma, the present study evaluated the effect of simultaneous suppression of human dishevelled‑3 (Dvl‑3) expression with Dvl‑3 small interfering RNA (siRNA) and of EGFR inhibition with gefitinib on mesothelioma cell viability. Mesothelioma cell lines with and without β‑catenin gene expression were transfected with Dvl‑3 siRNA and were cultured with gefitinib, and cell viability, colony formation and cell cycle analyses were performed. Dvl‑3 siRNA downregulated the expression of Dvl‑3 in mesothelioma cells. The combination of Dvl‑3 siRNA with gefitinib acted synergistically to induce concomitant suppression of cell viability and colony formation, suggesting that inhibition of Wnt signaling by downregulating Dvl‑3 with siRNA and inhibiting EGFR with gefitinib leads to significant antitumor effects.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Moriyama, G., Tanigawa, M., Sakai, K., Hirata, Y., Kikuchi, S., Saito, Y. ... Uematsu, K. (2018). Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro. Oncology Letters, 15, 833-838. https://doi.org/10.3892/ol.2017.7382
MLA
Moriyama, G., Tanigawa, M., Sakai, K., Hirata, Y., Kikuchi, S., Saito, Y., Kyoyama, H., Matsuda, K., Seike, M., Gemma, A., Uematsu, K."Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro". Oncology Letters 15.1 (2018): 833-838.
Chicago
Moriyama, G., Tanigawa, M., Sakai, K., Hirata, Y., Kikuchi, S., Saito, Y., Kyoyama, H., Matsuda, K., Seike, M., Gemma, A., Uematsu, K."Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro". Oncology Letters 15, no. 1 (2018): 833-838. https://doi.org/10.3892/ol.2017.7382